top of page
OUR DRUG PIPELINE
Promising disease product candidates for difficult to treat diseases
UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminephosphotransferase
(DPAGT1)
ANV221 & ANV322 - Defeating the Cancer Glycobiome
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)
bottom of page